QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
申请人:Qian Changgeng
公开号:US20080194578A1
公开(公告)日:2008-08-14
The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
Multi-Functional Small Molecules as Anti-Proliferative Agents
申请人:Cai Xiong
公开号:US20080221132A1
公开(公告)日:2008-09-11
The present invention relates to the compositions, methods, and applications of a novel approach to selective inhibition of several cellular or molecular targets with a single small molecule. More specifically, the present invention relates to multi-functional small molecules wherein one functionality is capable of inhibiting histone deacetylases (HDAC) and the other functionality is capable of inhibiting a different cellular or molecular pathway involved in aberrant cell proliferation, differentiation or survival.
MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS
申请人:Curis, Inc.
公开号:EP2061772A2
公开(公告)日:2009-05-27
US9024024B2
申请人:——
公开号:US9024024B2
公开(公告)日:2015-05-05
[EN] QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY<br/>[FR] INHIBITEURS D'EGFR À BASE DE QUINAZOLINE CONTENANT UN FRAGMENT DE LIAISON AU ZINC
申请人:CURIS INC
公开号:WO2008033749A2
公开(公告)日:2008-03-20
[EN] The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors. [FR] La présente invention concerne des dérivés à base de quinazoline contenant un fragment de liaison au zinc, qui présentent des propriétés améliorées et inattendues en tant qu'inhibiteurs de la tyrosine kinase du récepteur du facteur de croissance épidermique (EGFR-TK), ainsi que leur utilisation dans le traitement de maladies et de troubles associés à la EGFR-TK, notamment le cancer. Lesdits dérivés peuvent également faire office d'inhibiteurs d'HDAC.